Stem cell clinic patrol

  title={Stem cell clinic patrol},
  author={Stephen Strauss},
  journal={Nature Biotechnology},
885 closely scrutinized by prescribing physicians in deciding treatment options. In this instance, Peter Gøtzsche, director of the Nordic Cochrane Centre in Copenhagen, concluded that AAT augmentation therapy “cannot be recommended, in view of the lack of evidence of clinical benefit and the cost of treatment,” which can run to $150,000 annually for weekly infusions. The review examined data from the only two randomized clinical trials conducted in AAT, both produced by the same group of… CONTINUE READING